在炎症性肠道疾病中累积的蒂奥普林剂量和角质细胞皮肤癌:一个病例对照研究
Fenna M Jansen1, Nathan den Broeder1, Satish F K Lubeek2
1Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences.
European journal of gastroenterology & hepatology
|September 4, 2023
概括
对于那些接受氨酸治疗的炎症性肠病 (IBD) 患者来说,药物的累积剂量并没有增加质细胞皮肤癌 (KSC) 的风险. 年龄仍然是一个重要因素,这表明IBD患者需要个性化查.
科学领域:
- 皮肤病学 皮肤病学
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 用硫氨酸治疗的炎症性肠病 (IBD) 患者面临着皮细胞皮肤癌 (KSC) 的更高风险.
- 目前的指导方针建议这些患者每年进行皮肤学查.
- 蒂奥普林使用与KSC风险之间的剂量依赖关系尚不清楚.
研究的目的:
- 对IBD患者的累积蒂奥普林剂量和KSC发育之间的关联进行调查.
- 为IBD患者提供风险分层信息和个性化查建议.
- 为了澄清氨酸剂量在KSC发展中的作用.
主要方法:
- 进行了一项单一中心病例控制研究.
- 包括有IBD患者 (病例) 和没有 (对照) KSC的病史.
- 经过对年龄和吸烟情况进行调整后的后勤回归分析,评估了累积西奥普林剂量与KSC的相关性.
主要成果:
- 年龄和当前的阿扎西奥普林使用最初与KSC有关.
- 在多变量分析中,只有年龄仍然是一个重要的因素.
- 无论是累积的蒂奥普林剂量还是使用时间都没有显示出与KSC风险的显著关联.
结论:
- 累积的提奥普林剂量和持续时间与IBD患者的KSC发展无关.
- 在这个人群中,年龄是KSC的重要危险因素.
- 未来的风险分层应纳入多种因素,以优化IBD患者的皮肤学查.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease II: Crohn's Disease
285
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
285
Inflammatory Bowel Disease I: Ulcerative Colitis
213
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)

